Seizures, behavioral deficits, and adverse drug responses in two new genetic mouse models of HCN1 epileptic encephalopathy
Authors:
- Andrea MerseburgAMAndrea Merseburg
- Jacquelin KasemirJKJacquelin Kasemir
- Eric W BussEBEric W Buss
- Felix LeroyFLFelix Leroy
- Tobias BockTBTobias Bock
- Alessandro PorroAPAlessandro Porro
- Birgit EngelandBEBirgit Engeland
- Malte StockebrandMSMalte Stockebrand
- Anna MoroniAMAnna Moroni
- Steven A SiegelbaumSSSteven A Siegelbaum
Open Access
- 16 August 2022
- journal article
- research article
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
Abstract
De novo mutations in voltage- and ligand-gated channels have been associated with an increasing number of cases of developmental and epileptic encephalopathies, which often fail to respond to classic antiseizure medications. Here, we examine two knock-in mouse models replicating de novo sequence variations in the human HCN1 voltage-gated channel gene, p.G391D and p.M153I (Hcn1G380D/+ and Hcn1M142I/+ in mouse), associated with severe drug-resistant neonatal- and childhood-onset epilepsy, respectively. Heterozygous mice from both lines displayed spontaneous generalized tonic–clonic seizures. Animals replicating the p.G391D variant had an overall more severe phenotype, with pronounced alterations in the levels and distribution of HCN1 protein, including disrupted targeting to the axon terminals of basket cell interneurons. In line with clinical reports from patients with pathogenic HCN1 sequence variations, administration of the antiepileptic Na+ channel antagonists lamotrigine and phenytoin resulted in the paradoxical induction of seizures in both mouse lines, consistent with an impairment in inhibitory neuron function. We also show that these variants can render HCN1 channels unresponsive to classic antagonists, indicating the need to screen mutated channels to identify novel compounds with diverse mechanism of action. Our results underscore the necessity of tailoring effective therapies for specific channel gene variants, and how strongly validated animal models may provide an invaluable tool toward reaching this objective.Keywords
All Related Versions
Funding Information
- National Institutes of Health (NS106983)
- National Institutes of Health (NS109366)
- National Institutes of Health (NS123648)
- Deutsche Forschungsgemeinschaft (FOR 2715 (IS63/10-1/2))
- Deutsche Forschungsgemeinschaft (CRC 1451 (project ID 431549029 - B01))
- Fondazione Telethon (GGP20021)
This publication has 81 references indexed in Scilit:
- Nav1.1 haploinsufficiency in excitatory neurons ameliorates seizure-associated sudden death in a mouse model of Dravet syndromeHuman Molecular Genetics, 2013
- Novel blockers of hyperpolarization‐activated current with isoform selectivity in recombinant cells and native tissueBritish Journal of Pharmacology, 2011
- Neuron‐restrictive silencer factor‐mediated hyperpolarization‐activated cyclic nucleotide gated channelopathy in experimental temporal lobe epilepsyAnnals of Neurology, 2011
- HDAC inhibition modulates hippocampus-dependent long-term memory for object location in a CBP-dependent mannerLearning & Memory, 2011
- Increased Basal Synaptic Inhibition of Hippocampal Area CA1 Pyramidal Neurons by an Antiepileptic Drug that Enhances IHNeuropsychopharmacology, 2009
- TRIP8b Splice Variants Form a Family of Auxiliary Subunits that Regulate Gating and Trafficking of HCN Channels in the BrainNeuron, 2009
- HCN hyperpolarization-activated cation channels inhibit EPSPs by interactions with M-type K+ channelsNature Neuroscience, 2009
- Hyperpolarization activated cyclic-nucleotide gated (HCN) channels in developing neuronal networksProgress in Neurobiology, 2008
- HCN1 Channels Constrain Synaptically Evoked Ca2+ Spikes in Distal Dendrites of CA1 Pyramidal NeuronsNeuron, 2007
- Regulated expression of HCN channels and cAMP levels shape the properties of the h current in developing rat hippocampusEuropean Journal of Neuroscience, 2006